COVID-19 vaccine creates incentive to improve our health

Previous research suggests stress, depression, inactivity could interfere with immune response
Ohio State University
13-Jan-2021 2:00 PM EST, by Ohio State University

Newswise — COLUMBUS, Ohio – While we wait for our turn to get vaccinated against SARS-CoV-2, we could – and probably should – use the time to make sure we bring our healthiest emotional and physical selves to the treatment, a new review of previous research suggests. 

Ohio State University researchers reviewed 49 vaccine studies in humans dating back 30 years that document how stress, depression and poor health behaviors can negatively affect the body’s immune response to vaccination, and how improving health factors can enhance that response. 

The impaired immune responses tended to fall into three categories – interference with the development of antibodies against the pathogen, more rapid erosion of antibody protection that does develop, or intensification of vaccination’s side effects. 

The steady stress of navigating our disrupted routines and social lives during the pandemic may have set us back when it comes to maintaining healthy behaviors, the researchers say. They report on recent data from across the world documenting higher depressive and anxiety symptoms and more insomnia during lockdown, increased alcohol sales and overeating, and fewer average step counts recorded by Fitbits. 

There is good news: The power to make improvements that give us the best chance for a healthy response to the coronavirus vaccine is almost completely in our control. Managing stress through exercise and mindfulness meditation, getting enough sleep, quitting or curbing tobacco use and improving our diets – even in the short term, right around the time of vaccination – could influence how our bodies respond, the evidence suggests. And for those struggling with depression, now would be a good time to seek professional help. 

“When we think of vaccine efficacy, we often think of the vaccine itself. My motivation was to draw attention to the fact that we bring important factors to the table as well – and those factors are modifiable,” said Annelise Madison, first author of the paper and a graduate student in clinical psychology at Ohio State. 

“If we can address them now, when most of the world has yet to receive the vaccine, we have the chance to make our response to the vaccine quicker, more robust and lasting.” 

A number of the studies reviewed were led by senior author Janice Kiecolt-Glaser, director of Ohio State’s Institute for Behavioral Medicine Research and a professor of psychiatry and psychology in the College of Medicine. Kiecolt-Glaser and her late husband, immunologist Ronald Glaser, were pioneers in mind-body research that showed how stress impairs physical health in a variety of ways, primarily by hampering the human immune response. 

The review is accepted for publication in the journal Perspectives on Psychological Science

The studies in this review investigated the effects of psychological factors and behaviors on the immune response to a range of vaccine types, such as influenza, hepatitis B, typhoid and pneumonia. Because many findings have been consistent across responses to different vaccines, the team considered them likely to be relevant to the SARS-CoV-2 vaccine. 

Kiecolt-Glaser pointed to a few of her past studies that illustrate the varying effects of different types of stress on human responses to vaccination. 

In a study of medical students’ immune response to a highly effective hepatitis B vaccine, all students eventually developed antibodies – but the students who were more stressed or anxious about exams coinciding with the inoculations took significantly longer to develop protective antibodies. 

Research on older adults’ response to a pneumococcal pneumonia vaccine showed that though all study participants initially developed antibodies quickly, the antibody response diminished over the next three to six months in those who were chronically stressed caregivers looking after spouses with dementia. 

“These findings suggest that with the COVID-19 vaccine, when people are more stressed and more anxious, it may take a little longer to develop antibodies, so they should probably allow a little more time before they assume they’re protected,” Kiecolt-Glaser said. “Another possibility is that stress may erode protection more rapidly.” 

Her lab’s past research has also shown that older adults – who are considered at higher risk for severe COVID-19 symptoms – sometimes don’t respond well to flu vaccines. In one study, only 20% of stressed adults who were age 71 or older developed antibodies after a flu shot. 

Additional studies in her lab showed that people who were depressed experienced post-vaccination side effects of lethargy, malaise and irritability for a longer period of time than people who were not depressed. 

Side effects are normal – the vaccination is training the immune system to recognize a pathogen by initiating an inflammatory response that can make us feel sick – but they can cause some people to avoid vaccines. 

“Side effects are from an inflammatory response to the vaccine, which is a good thing,” Kiecolt-Glaser said. “You want to see a strong response to the vaccine. That’s one reason we know the vaccine is effective. On the other hand, the absence of a response doesn’t mean it’s not effective.” 

According to previous research, a range of interventions may help us all get the most out of the COVID-19 vaccine: Massage and expressive writing for stress management, short- and long-term physical activity including 25 minutes of arm exercises before injection, and nutritional supplementation all helped increase antibody response or reduce side effects in past studies. 

“And when you know you’re going to get the vaccine the next day, try to get a good night’s sleep. Just one night, and going in fully rested, can be helpful,” Kiecolt-Glaser said. 

Though we may be suffering from health-advice fatigue 10 months after the first lockdown, Madison said now may be the most important time to heed the experts’ recommendations. 

“I know it can be difficult day in and day out during the pandemic to keep prioritizing things we know we should do,” she said. “But we could use this time as a wake-up call. These are important health behaviors to keep engaging in, especially as we’re preparing to get vaccinated – which is a really good thing.” 

Research reviewed in the paper was supported by grants from the National Institutes of Health. Additional co-authors were Rosie Shrout and Megan Renna of the Institute for Behavioral Medicine Research.

 

#

 

 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.


Showing results

110 of 4573

close
1.1944